7 research outputs found
ΠΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ΅Ρ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ½ΠΎΠΉ ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π°ΠΌΠ»ΠΎΠ΄ΠΈΠΏΠΈΠ½Π°, ΠΈΠ½Π΄Π°ΠΏΠ°ΠΌΠΈΠ΄Π° ΠΈ ΠΏΠ΅ΡΠΈΠ½Π΄ΠΎΠΏΡΠΈΠ»Π° Π°ΡΠ³ΠΈΠ½ΠΈΠ½Π° Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅: ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ ΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ ΠΠΠΠΠΠΠ’ΠΠΠ¬Π‘Π’ΠΠ
Aim: to assess antihypertensive efficacy of the fixed-dose amlodipine/indapamide/perindopril arginine combination in hypertensive patients in real clinical setting. Methods. We included in the 3-month clinical program 1 599 patients with arterial hypertension (AH) (38.8 % men, mean age 61.6Β±10 years). Primary outcomes were change of office and ambulatory (home blood pressure monitoring) systolic and diastolic blood pressure (SBP and DBP) from baseline to 3 months and rate of achievement of target BP<140 /90 mmHg. Secondary outcomes included response to the therapy, adherence to treatment and safety. Results. By 3 months office BP decreased from 165.5Β±15.3/96.2Β±9.7 to 127.6Β±8.5/78.3Β±6.4 mmHg (Ρ<0.001); ambulatory BP - from 146.8Β±13.0/86.4Β±7.8 to 128.6Β±9.0/78.2Β±5.6 mm Hg (Ρ<0.001). Target office BP <140/90 and ambulatory BP<135/85 mmHg was achieved in 87 and 68.1% of patients, respectively. Adherence score increased from 2.9Β±1.6 Π΄ΠΎ 5.1Β±1.0 (Ρ<0.001). Conclusion. Administration of a fixed-dose amlodipine/indapamide/perindopril arginine combination resulted in significant BP decrease and rapid achievement of target office BP in most patients. The combination was safe and well tolerated.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠ΅Π½ΠΊΠ° Π°Π½ΡΠΈΠ³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ²Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π°ΠΌΠ»ΠΎΠ΄ΠΈΠΏΠΈΠ½/ΠΈΠ½Π΄Π°ΠΏΠ°ΠΌΠΈΠ΄/ΠΏΠ΅ΡΠΈΠ½Π΄ΠΎΠΏΡΠΈΠ»Π° Π°ΡΠ³ΠΈΠ½ΠΈΠ½ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΠ΅ΠΉ (ΠΠ) Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π½Π°ΡΡΠ½ΠΎ-ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΡΡ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 1599 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ (38,8% ΠΌΡΠΆΡΠΈΠ½, ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 61,6Β±10 Π»Π΅Ρ), Π²ΡΠ΅ΠΌ Π½Π°Π·Π½Π°ΡΠ΅Π½ ΡΡΠΈΠΏΠ»ΠΈΠΊΡΠ°ΠΌ Π² ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· 4 Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΡ
Π΄ΠΎΠ·ΠΈΡΠΎΠ²ΠΎΠΊ Π½Π° 3 ΠΌΠ΅Ρ. ΠΡΠ½ΠΎΠ²Π½Π°Ρ ΡΠ΅Π»Ρ: Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΠ ΠΏΡΠΈ ΡΠ°ΠΌΠΎΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ ΠΎΡ Π²ΠΈΠ·ΠΈΡΠ° 1 ΠΊ Π²ΠΈΠ·ΠΈΡΡ 4 ΠΈ ΡΠ°ΡΡΠΎΡΠ° Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΡΠ΅Π»Π΅Π²ΠΎΠ³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄Π°Π²Π»Π΅Π½ΠΈΡ (ΠΠ) <140/90 ΠΌΠΌ ΡΡ. ΡΡ. ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ. ΠΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Π»ΠΈ: ΡΠ°ΡΡΠΎΡΠ° ΠΎΡΠ²Π΅ΡΠ° Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅, ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΡ, Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π§Π΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΠ (Π‘ΠΠ) ΡΠ½ΠΈΠ·ΠΈΠ»ΠΎΡΡ Ρ 165,5Β±15,3 Π΄ΠΎ 127,6Β±8,5 ΠΌΠΌ ΡΡ. ΡΡ., Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΠ (ΠΠΠ) - Ρ 96,2Β±9,7 Π΄ΠΎ 78,3Β±6,4 ΠΌΠΌ ΡΡ. ΡΡ. (Ρ<0,001). ΠΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΠΎΠ΅ ΡΡΡΠ΅Π½Π½Π΅Π΅ Π‘ΠΠ ΡΠ½ΠΈΠ·ΠΈΠ»ΠΎΡΡ Ρ 146,8Β±13,0 Π΄ΠΎ 128,6Β±9,0 ΠΌΠΌ ΡΡ. ΡΡ., ΠΠΠ - Ρ 86,4Β±7,8 Π΄ΠΎ 78,2Β±5,6 ΠΌΠΌ ΡΡ. ΡΡ. (Ρ<0,001). Π§Π°ΡΡΠΎΡΠ° Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΠ<140/90 ΠΌΠΌ ΡΡ. ΡΡ. ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 87%, Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΠ <135/85 ΠΌΠΌ ΡΡ. ΡΡ. - 68,1%. ΠΡΠ΅Π½ΠΊΠ° ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ²Π΅Π»ΠΈΡΠΈΠ»Π°ΡΡ Ρ 2,9Β±1,6 Π΄ΠΎ 5,1Β±1,0 Π±Π°Π»Π»Π° (Ρ<0,001). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΡΠΈΠΏΠ»ΠΈΠΊΡΠ°ΠΌΠ° ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅ΡΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΠ Π½Π° 38/18 ΠΌΠΌ ΡΡ. ΡΡ. ΠΈ Π±ΡΡΡΡΡΠΌ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΠ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Ρ Ρ
ΠΎΡΠΎΡΠ°Ρ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΡ ΠΈ Π²ΡΡΠΎΠΊΠ°Ρ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°
ΠΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ΅Ρ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ½ΠΎΠΉ ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π°ΠΌΠ»ΠΎΠ΄ΠΈΠΏΠΈΠ½Π°, ΠΈΠ½Π΄Π°ΠΏΠ°ΠΌΠΈΠ΄Π° ΠΈ ΠΏΠ΅ΡΠΈΠ½Π΄ΠΎΠΏΡΠΈΠ»Π° Π°ΡΠ³ΠΈΠ½ΠΈΠ½Π° Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅: ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ ΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ ΠΠΠΠΠΠΠ’ΠΠΠ¬Π‘Π’ΠΠ
Aim: to assess antihypertensive efficacy of the fixed-dose amlodipine/indapamide/perindopril arginine combination in hypertensive patients in real clinical setting. Methods. We included in the 3-month clinical program 1 599 patients with arterial hypertension (AH) (38.8 % men, mean age 61.6Β±10 years). Primary outcomes were change of office and ambulatory (home blood pressure monitoring) systolic and diastolic blood pressure (SBP and DBP) from baseline to 3 months and rate of achievement of target BP<140 /90 mmHg. Secondary outcomes included response to the therapy, adherence to treatment and safety. Results. By 3 months office BP decreased from 165.5Β±15.3/96.2Β±9.7 to 127.6Β±8.5/78.3Β±6.4 mmHg (Ρ<0.001); ambulatory BP - from 146.8Β±13.0/86.4Β±7.8 to 128.6Β±9.0/78.2Β±5.6 mm Hg (Ρ<0.001). Target office BP <140/90 and ambulatory BP<135/85 mmHg was achieved in 87 and 68.1% of patients, respectively. Adherence score increased from 2.9Β±1.6 Π΄ΠΎ 5.1Β±1.0 (Ρ<0.001). Conclusion. Administration of a fixed-dose amlodipine/indapamide/perindopril arginine combination resulted in significant BP decrease and rapid achievement of target office BP in most patients. The combination was safe and well tolerated.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠ΅Π½ΠΊΠ° Π°Π½ΡΠΈΠ³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ²Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π°ΠΌΠ»ΠΎΠ΄ΠΈΠΏΠΈΠ½/ΠΈΠ½Π΄Π°ΠΏΠ°ΠΌΠΈΠ΄/ΠΏΠ΅ΡΠΈΠ½Π΄ΠΎΠΏΡΠΈΠ»Π° Π°ΡΠ³ΠΈΠ½ΠΈΠ½ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΠ΅ΠΉ (ΠΠ) Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π½Π°ΡΡΠ½ΠΎ-ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΡΡ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 1599 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ (38,8% ΠΌΡΠΆΡΠΈΠ½, ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 61,6Β±10 Π»Π΅Ρ), Π²ΡΠ΅ΠΌ Π½Π°Π·Π½Π°ΡΠ΅Π½ ΡΡΠΈΠΏΠ»ΠΈΠΊΡΠ°ΠΌ Π² ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· 4 Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΡ
Π΄ΠΎΠ·ΠΈΡΠΎΠ²ΠΎΠΊ Π½Π° 3 ΠΌΠ΅Ρ. ΠΡΠ½ΠΎΠ²Π½Π°Ρ ΡΠ΅Π»Ρ: Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΠ ΠΏΡΠΈ ΡΠ°ΠΌΠΎΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ ΠΎΡ Π²ΠΈΠ·ΠΈΡΠ° 1 ΠΊ Π²ΠΈΠ·ΠΈΡΡ 4 ΠΈ ΡΠ°ΡΡΠΎΡΠ° Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΡΠ΅Π»Π΅Π²ΠΎΠ³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄Π°Π²Π»Π΅Π½ΠΈΡ (ΠΠ) <140/90 ΠΌΠΌ ΡΡ. ΡΡ. ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ. ΠΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Π»ΠΈ: ΡΠ°ΡΡΠΎΡΠ° ΠΎΡΠ²Π΅ΡΠ° Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅, ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΡ, Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π§Π΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΠ (Π‘ΠΠ) ΡΠ½ΠΈΠ·ΠΈΠ»ΠΎΡΡ Ρ 165,5Β±15,3 Π΄ΠΎ 127,6Β±8,5 ΠΌΠΌ ΡΡ. ΡΡ., Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΠ (ΠΠΠ) - Ρ 96,2Β±9,7 Π΄ΠΎ 78,3Β±6,4 ΠΌΠΌ ΡΡ. ΡΡ. (Ρ<0,001). ΠΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΠΎΠ΅ ΡΡΡΠ΅Π½Π½Π΅Π΅ Π‘ΠΠ ΡΠ½ΠΈΠ·ΠΈΠ»ΠΎΡΡ Ρ 146,8Β±13,0 Π΄ΠΎ 128,6Β±9,0 ΠΌΠΌ ΡΡ. ΡΡ., ΠΠΠ - Ρ 86,4Β±7,8 Π΄ΠΎ 78,2Β±5,6 ΠΌΠΌ ΡΡ. ΡΡ. (Ρ<0,001). Π§Π°ΡΡΠΎΡΠ° Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΠ<140/90 ΠΌΠΌ ΡΡ. ΡΡ. ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 87%, Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΠ <135/85 ΠΌΠΌ ΡΡ. ΡΡ. - 68,1%. ΠΡΠ΅Π½ΠΊΠ° ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ²Π΅Π»ΠΈΡΠΈΠ»Π°ΡΡ Ρ 2,9Β±1,6 Π΄ΠΎ 5,1Β±1,0 Π±Π°Π»Π»Π° (Ρ<0,001). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΡΠΈΠΏΠ»ΠΈΠΊΡΠ°ΠΌΠ° ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅ΡΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΠ Π½Π° 38/18 ΠΌΠΌ ΡΡ. ΡΡ. ΠΈ Π±ΡΡΡΡΡΠΌ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΠ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Ρ Ρ
ΠΎΡΠΎΡΠ°Ρ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΡ ΠΈ Π²ΡΡΠΎΠΊΠ°Ρ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°
Fixed-dose combination of amlodipine/indapamide/perindopril arginine β a rational and safe choice for blood pressure control in actual clinical setting: Data of an observational program DOKAZATEL`STVO
Aim. To analyze the efficacy and tolerability of amlodipine/indapamide/perindopril arginine (Triplixam) in a subgroup of 790 people participating in the Russian observational program DOKAZATEL`STVO without use of other antihypertensive agents. Material and methods. The analysis included 790 patients with hypertension (HTN) (men β 37,9%, mean age β 60,0Β±10,2 years). The drug was administrated in one of 4 recommended dosages for 3 months. We assessed the dynamics of office and home blood pressure (BP) from visit 1 to visit 4 and the frequency of achieving the target BP <140/90 mm Hg in 3 months. Results. After 3 months, office systolic BP (SBP) decreased from 163,4Β±14,0 to 127,2Β±7,8 mm Hg, diastolic BP (DBP) β from 95,7Β±9,5 to 78,3Β±6,2 mm Hg (p<0,001). Home SBP in the morning decreased from 145,9Β±12,3 to 128,3Β±7,8 mm Hg, DBP β from 86,2Β±7,7 to 78,4Β±5,6 mm Hg (p<0,001). After 3 months, target office BP (<140/90 mm Hg) was achieved in 88,4% of subjects, home BP (<135/85 mm Hg) β 73%. Conclusion. The administration of Triplixam without additional antihypertensive agents results in a significant BP decrease by 36/17 mm Hg and rapid achievement of BP control in most patients. The combination is safe and well tolerated. Β© 2020, Silicea-Poligraf. All rights reserved
Office and 44-hour ambulatory blood pressure and central haemodynamic parameters in the patients with end-stage renal diseases undergoing haemodialysis
AIM: To assess the incidence of blood pressure (BP) control and various phenotypes of BP by comparing the results of office and 44-hour ambulatory brachial and central BP measurement in patients with end-stage renal disease (ESRD) on program hemodialysis (HD). MATERIALS AND METHODS: In 68 patients ESRD receiving renal replacement therapy we evaluated office peridialysis BP and performed 44-hour ambu latory monitoring (ABPM) of brachial and central BP during peridialysis period using a validated oscillometric device BPLabVasotens (OOO "Petr Telegin"). Results were considered statistically significant with p<0.05. RESULTS: The frequency of control of peripheral office BP before the HD session was 25%, after - 23.5%; control of central BP - 48.6% and 49%, respectively. According to office measurement the frequency of systolic-diastolic hypertension was 44.1%, isolated systolic hypertension - 25%, isolated diastolic hypertension - 5.9%. The values of peripheral and central office systolic BP (SBP) before and after HD were not consistent with the corresponding mean and daily SBP levels for 44 hours and for the first and second days of the interdialysis period. The frequency of true uncontrolled arterial hypertension (AH) according to peripheral ABPM was 66.5%, masked uncontrolled AH - 9%. Circadian rhythm abnormalities for 44-h peripheral BP were detected in 77%, for central - in 76%. In 97% of patients agreement between phenotypes of the daily profile of peripheral and central BP was observed. 73% of patients had a significant increase in peripheral and central SBP and pulse pressure (PP) and an increase in the proportion of non-dippers from the 1st to the 2nd day. CONCLUSION: Patients with ESRD on HD were characterized by poor control of BP control and predominance of unfavourable peripheral and central ambulatory BP phenotypes. A single measurement of clinical peripheral and central BP in the peridialysis period was not sufficient to assess the control of hypertension in this population. The 24-h BP profiles in the 1st and 2nd days of interdialysis period had significant differences